Search Within

David Solit

Formats
  1. Meeting Abstract (391)
  2. Journal Article (366)
  3. Editorial (9)
  4. Book Section (4)
  5. Research Letter (4)
  6. Review (4)
  7. Correspondence (2)
  8. Guidelines (2)
  9. Conference Paper (1)
Groups
  1. Department of Medicine (783)
  2. GSK Faculty (783)
  3. Genitourinary Oncology Service (783)
  4. Human Oncology and Pathogenesis Program (783)
  5. Solid Tumor Oncology Division (783)
  6. Department of Pathology and Laboratory Medicine (510)

More Groups

People
  1. Michael Berger (317)
  2. Hikmat Al-Ahmadie (186)
  3. Gopakumar Iyer (184)
  4. Neal Rosen (155)
  5. Nikolaus Schultz (150)
  6. Dean Bajorin (130)

More People

Years
  1. 2025 (17)
  2. 2024 (38)
  3. 2023 (39)
  4. 2022 (44)
  5. 2021 (47)
  6. 2020 (59)

More Years

Publications
  1. Journal of Clinical Oncology (163)
  2. Cancer Research (99)
  3. Clinical Cancer Research (77)
  4. Laboratory Investigation (42)
  5. Modern Pathology (37)
  6. Cancer Discovery (24)

More Publications

Publishers
  1. American Association for Cancer Research (219)
  2. American Society of Clinical Oncology (181)
  3. Nature Publishing Group (97)
  4. Nature Research (39)
  5. Elsevier Inc. (31)
  6. Oxford University Press (29)

More Publishers

Results (783)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I/II study of docetaxel and (153)Sm for castrate metastatic prostate cancer (CMPC): Summary of dose-escalation cohorts and first report on the expansion cohort
    Meeting Abstract

    Morris, M. J.; Pandit-Taskar, N.; Stephenson, R. D.; Hong, C.; Slovin, S. F.; Rathkopf, D.; Solit, D.; Carrasquillo, J.; Larson, S.; Scher, H. I.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Genetic predictors of MEK dependence in V600E BRAF mutant melanoma
    Meeting Abstract

    Xing, F.; Pratilas, C.; Persaud, Y.; Janakiraman, M.; Houghton, A.; Rosen, N.; Solit, D.
    Cancer Research (2009)

    Fulltext@MSK | Save
  • Identification and biological characterization of exon 4 KRAS mutations by MALDI-TOF Mass Spectrometry based genotyping
    Meeting Abstract

    Janakiraman, M.; Zeng, Z.; Chitale, D.; Halilovic, E.; Rosen, N.; Vakiani, E.; Heguy, A.; Ladanyi, M.; Jhanwar, S.; Saltz, L.; more...
    Cancer Research (2009)

    Fulltext@MSK | Save
  • Amplification of wild-type BRAF in melanoma is associated with activation of RAF-MEK-ERK signaling and MEK-dependence
    Meeting Abstract

    Blumenthal, E.; Poulikakos, P. I.; Tadi, M.; Grbovic-Huezo, O.; Taylor, B. S.; Janakiraman, M.; Leversha, M.; Viale, A.; Solit, D. B.; Rosen, N.; more...
    Cancer Research (2009)

    Fulltext@MSK | Save
  • PIK3CA and AKT1 mutations are independent in invasive breast cancer
    Meeting Abstract

    Moynahan, M. E.; Heguy, A.; Drobnjak, M.; Traina, T.; Howard, J.; Patil, S.; Gerald, W.; Solit, D.; Hudis, C.
    Cancer Research (2009)

    Fulltext@MSK | Save
  • Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer
    Journal Article

    Morris, M. J.; Pandit-Taskar, N.; Carrasquillo, J.; Divgi, C. R.; Slovin, S.; Kelly, W. K.; Rathkopf, D.; Gignac, G. A.; Solit, D.; Schwartz, L.; more...
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers
    Journal Article

    Veeriah, S.; Brennan, C.; Meng, S.; Singh, B.; Fagin, J. A.; Solit, D. B.; Paty, P. B.; Rohle, D.; Vivanco, I.; Chmielecki, J.; more...
    Proceedings of the National Academy of Sciences of the United States of America (2009)

    Fulltext@MSK | Save
  • Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer
    Journal Article

    Riely, G. J.; Rizvi, N. A.; Kris, M. G.; Milton, D. T.; Solit, D. B.; Rosen, N.; Senturk, E.; Azzoli, C. G.; Brahmer, J. R.; Sirotnak, F. M.; more...
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1
    Journal Article

    Ricarte-Filho, J. C.; Ryder, M.; Chitale, D. A.; Rivera, M.; Heguy, A.; Ladanyi, M.; Janakiraman, M.; Solit, D.; Knauf, J. A.; Tuttle, R. M.; more...
    Cancer Research (2009)

    Fulltext@MSK | Save
  • V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
    Journal Article

    Pratilas, C. A.; Taylor, B. S.; Ye, Q.; Viale, A.; Sander, C.; Solit, D. B.; Rosen, N.
    Proceedings of the National Academy of Sciences of the United States of America (2009)

    Fulltext@MSK | Save